GlassScriptPhysician profile
Omair Atiq
NPI 1336455260
$3,111.60
in general payments reported to CMS, 2019-2025
26 companies · $703 in 2025
The $703 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $90.21 · 2020: $21.41 · 2021: $12.68 · 2022: $388 · 2023: $416 · 2024: $1,481 · 2025: $703.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,931 · Travel and Lodging: $652 · Education: $15.93.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,931.38 |
| Travel and Lodging | $651.92 |
| Education | $15.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $982.55 | 2019-2025 | Skyrizi, Rinvoq, Mavyret |
| Boston Scientific Corporation | $759.10 | 2021-2024 | |
| Gilead Sciences, INC. | $328.01 | 2023-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $144.33 | 2022-2025 | Xifaxan, Trulance, Plenvu |
| Takeda Pharmaceuticals U.S.A., INC. | $103.85 | 2025 | Entyvio, Gattex |
| Astrazeneca Pharmaceuticals LP | $66.34 | 2022-2024 | Andexxa |
| Madrigal Pharmaceuticals | $63.07 | 2024-2025 | Rezdiffra, Resmetirom |
| Redhill Biopharma INC. | $60.04 | 2022-2023 | Talicia |
| Cook Medical LLC | $59.88 | 2019 | |
| Intercept Pharmaceuticals, INC. | $57.39 | 2022-2025 | Ocaliva |
| Braintree Laboratories, INC. | $55.36 | 2022-2023 | Suflave |
| Aimmune Therapeutics, INC. | $51.33 | 2025 | Zenpep |
| Daiichi Sankyo INC. | $48.88 | 2022 | |
| Nestle Healthcare Nutrition INC. | $48.82 | 2023 | |
| Lilly USA, LLC | $45.57 | 2024 | Omvoh |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $35.17 | 2024-2025 | Stelara, Tremfya |
| Qol Medical, LLC | $25.42 | 2023 | Sucraid |
| Phathom Pharmaceuticals, INC. | $24.44 | 2025 | Voquezna |
| Regeneron Healthcare Solutions, INC. | $23.72 | 2025 | Dupixent |
| Alcresta Therapeutics, INC. | $21.74 | 2024 | Relizorb |
| Recordati_rare_diseases_inc. | $20.27 | 2025 | Panhematin |
| Dynavax Technologies Corporation | $18.88 | 2022 | |
| Ferring Pharmaceuticals INC. | $17.99 | 2022 | |
| Endogastric Solutions, INC | $16.83 | 2022 | |
| Concordia Pharmaceuticals INC. | $16.74 | 2019 | |
| Vivus LLC | $15.88 | 2023 | Qsymia |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Omair Atiq listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.